Stephen Yiu Chuen Choi

Stephen Yiu Chuen Choi is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer therapeutics, particularly through his innovative work on monocarboxylate transporter (MCT) antisense oligonucleotide (ASO) inhibitors. With a total of 2 patents, his research focuses on modulating MCT4 activity to improve cancer treatment outcomes.

Latest Patents

Choi's latest patents include compositions and methods for using MCT antisense oligonucleotides as therapeutics in the treatment of various cancers. These compositions are designed for administration to cancer cells characterized by elevated expression of MCT4. The cancers targeted by his inventions include prostate cancer, renal cell carcinoma, breast cancer, cervical cancer, liver cancer, bladder cancer, and small cell lung cancer. Notably, his work addresses castration-resistant prostate cancer (CRPC), providing new avenues for treatment.

Career Highlights

Stephen Yiu Chuen Choi is affiliated with the University of British Columbia, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential to significantly impact cancer treatment protocols and improve patient outcomes.

Collaborations

Choi collaborates with Yuzhuo Wang, contributing to the development of innovative cancer therapies. Their partnership exemplifies the collaborative spirit in research that drives advancements in medical science.

Conclusion

Stephen Yiu Chuen Choi's contributions to cancer treatment through his patented innovations highlight the importance of research in developing effective therapies. His work continues to pave the way for future advancements in the field of oncology.

Profile summary based on public USPTO records.